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Abstract 
Regulation of cell division in adult tissues and organs requires the coordination of growth factors 
at the surface of potentially-dividing cells in specific anatomic loci named germinal niches. 
However, the biological components and physiological system that control growth factors in the 
germinal niches are unknown. In the adult brain, no function has been attributed to fractones, the 
fractal-shaped extracellular matrix structures located in the subventricular zone (SVZ) next to 
neural stem and progenitor cells. Here, we show that BMP-7 (bone morphogenetic protein-7) and 
FGF-2 (fibroblast growth factor-2) modulate cell division in the SVZ only if the growth factors 
bind to heparan sulfates localized in fractones and adjoined vascular basement membranes. Our 
results strongly suggest that fractones and specialized basement membranes function as stem cell 
niche structures, capturing and potentiating growth factors to regulate cell division in the adult 
brain.  
 
Introduction 
    We previously identified extracellular matrix (ECM) structures in the adult mammalian 
brain1,2 that differ from the three recognized categories of ECM, namely the interstitial matrix, 
the basement membrane and the glycocalyx3-6. This new ECM consists of myriads of individual 
fractal-shaped microstructures that we have named fractones1. The fractal structure7, unique 
amongst the ECM, allows each individual fractone to contact the processes of numerous 
neighboring cells in a minimal space1,2. This is illustrated here in Figs. 1a-1c. Due to their high 
electron density, the fractone ultrastructure is directly visible by transmission electron 
microscopy (Figs. 1b and 1c). However, fractones are too small to be visualized as fractals by 
light microscopy and appear as punctae after fluorescence immunolabeling for laminin (Fig. 1f), 
nidogen, collagen-IV or heparan sulfate proteoglycans (HSPG) (Fig. 1d) and1,2,8.  These 
molecules are also found in basement membranes9-11, the specialized mats of ECM that interface 
connective tissue with the parenchyma of organs and tissues. Thus, despite their unique 
morphology, fractones chemically resemble basement membranes.  
    In the adult mammalian brain, fractones are exclusively located in the walls bordering the 
ventricles, assembled in series at the interface between the ependyma and the subventricular zone 
(SVZ) (Figs. 1d-1f). The distribution of fractones and their arrangement through the SVZ is best 
visualized tangentially to the ventricular surface after immunolabeling for its ECM molecules 
(Fig. 1f). Fractones are similarly distributed throughout the brain ventricular system and spinal 
subependyma1,2,8. 
    We are just beginning to investigate the function of fractones. We have previously shown that 
fractones directly contact neuroblasts and potential neural stem cells in the SVZ of the anterior 
lateral ventricle (SVZa)1, the principal residence of neural stem cells12,13  and a major neurogenic 
zone in adulthood14,17. The SVZa is responsible for the generation of both neurons and glia, 
which then migrate to colonize other brain zones18. We also demonstrated that fractones and 
specialized blood vessels of the SVZa specifically capture and concentrate the 
mitotic/neurogenic factor fibroblast growth factor-2 (FGF-2) in vivo8. Based on these findings, 
we hypothesize that fractones participate to the regulation of cell division and cell differentiation 
in the SVZa. It is anticipated that regulation of cell division and cell differentiation by growth 
factors requires mechanisms of selection, activation and coordination of growth factors in the 
stem cell niches. Fractones and other ECM may perform this function via HSPG and chondroitin 
sulfate proteoglycans (CSPG). It is known that HSPG located in the extracellular space capture, 
store and target growth factors such as fibroblast growth factor-2 (FGF-2), granulocyte 
macrophage colony stimulating factor (GM-CSF) and bone morphogenetic protein-4 (BMP-4) 
towards cell surface receptors to control mitosis and cell differentiation19-24. Nearly all growth 
factors, cytokines and chemokines are heparin-binding molecules, therefore potentially depend 
upon extracellular HSPG to recognize their cognate receptors at the cell surface.  Do fractones 
and basement membranes coordinate growth factor signaling through their HSPG to modulate 
cell proliferation and cell differentiation in the stem cell niches? 
    Here, we focused our work on the role of heparan sulfates, concentrated in fractones and 
vascular basement membranes, as potential regulators of cell division in the adult neural stem 
cell niche. We used intracerebral injections of growth factors, heparan sulfate deglycanation in 
vivo by heparitinase-1, mapping growth factor binding in situ, immunolabeling for heparan 
sulfates and quantification of cell division by bromodeoxyuridine (BrdU) immunolabelings to 
investigate the role of fractones and vascular basement membranes in the SVZa. Herein, we 
demonstrate that BMP-7 and FGF-2 must bind heparan sulfates present in fractones and vascular 
basement membranes to respectively inhibit and stimulate cell division in the SVZa.  
 
Results 
 Fractones and vascular basement membranes of the SVZa capture BMP-7   
    To investigate the potential of fractones to capture growth factors, we 
intracerebroventricularly (ICV) injected BMP-7 tagged with biotin in the adult mouse brain. The 
sites of capture (binding) of biotinylated-BMP-7 were visualized with streptavidin Texas red on 
frozen sections of the brain, 22 hours after injection. Figure 2a shows biotinylated BMP-7 
concentrated as punctae in the SVZa, a diffuse pattern in the choroid plexus, and no detectable 
binding elsewhere. Immunolabeling for the ECM marker N-sulfates heparan sulfates (NS-HS, 
antibody 10E4) (Fig. 2b), a specific specific for fractones, meninges and rare blood vessels 
(primarily those of the SVZa)8, indicated a correspondence between BMP-7 binding sites and 
10E4 immunoreactivity (compare Figs. 2a and 2b). Magnified fields in Figs. 2c and 2d revealed 
that the majority of BMP-7 binding sites were sharp punctae with a diameter < 5 µm 
corresponding to fractones. However, we also detected BMP-7 binding sites/10E4 
immunolabeled structures that correspond to the typical cylindrical pattern of blood vessels with 
a diameter > 6 µm). The distinction between fractones and blood vessels of the SVZa by the 
morphological pattern of 10E4 or laminin immunolabeling is discussed in our previous 
publications1,2,8. The strict coincidence between the binding sites of BMP-7 and immunolabeling 
for 10E4 strongly suggests that BMP-7 binds to fractones and to the basement membranes of 
blood vessels supplying the SVZa. The position of vascular basement membranes within the 
blood vessel walls and the typical branched pattern of vascular basement membranes in the 
SVZa are documented in our previous publications1, 25, 26. 
    Interestingly, blood vessels located beyond the SVZa did not significantly bind BMP-7, as 
illustrated by the absence of detectable binding in the corpus callosum or fimbria hippocampus in 
Fig. 2a. Therefore, BMP-7 specifically bound to blood vessels in the SVZa, immunoreactive for 
NS-HS and visualized with the antibody 10E4. Figures 2h and 2i show that BMP-7 was also 
concentrated by fractones and vascular basement membranes in the walls of the fourth ventricle 
(arrow) and meninges projecting to the fourth ventricle (arrowhead). BMP-7 binding occurred in 
fractones of the third ventricle as well (not shown). 
   
Co-localisation of BMP-7 binding sites with N-sulfated heparan sulfate domains  
    Deglycanation by heparitinase-1 was used to cleave heparan sulfate chains in vivo and to 
determine whether the binding of BMP-7 to fractones and SVZa blood vessels still occurs 
without heparan sulfates. Under these experimental conditions, the binding of BMP-7 
disappeared completely from fractones and blood vessels (Fig. 2f). This strongly suggests that 
the binding of BMP-7 occurred via heparan sulfates.  
 
BMP-7 inhibits cell division in vivo in the SVZa 
    We next determined the effect of BMP-7 on cell proliferation in the SVZa. BMP-7 is an 
inhibitor of NSC proliferation in vitro27, but to our knowledge, BMP-7’s anti-neurogenic activity 
has not been demonstrated in vivo. Two single injections of BMP-7 were performed in adult 
mice, and the effect on cell proliferation measured four days after the first injection. To visualize 
cells that initiate mitosis (DNA replication, phase S), a single intraperitoneal injection of 
bromodeoxyuridine (BrdU) was performed six hours prior to animal termination. BrdU-
immunoreactive cells were counted on series of coronal frozen sections containing the anterior 
portion of the lateral ventricle, each series on a minimum of three animals. Figures 3a and 3b 
show that BMP-7 strongly inhibited mitosis phase S in the SVZa. A reduction of cell 
proliferation by a factor of 3.5 was observed relative to the control (ICV injection with artificial 
CSF, Fig. 3a). Average values for cell counts throughout brain sections are reported in Fig. 3d 
and Table 1 (supplementary results). We did not observe significant cell count differences in the 
ipsi- and contra-lateral ventricles. This indicated that BMP-7 penetrated the brain and equally 
inhibited cell division on both sides.  
 
BMP-7 cannot efficiently inhibit cell proliferation in the SVZa when co-injected with 
heparitinase-1 
    To determine whether BMP-7 binding to fractones and vascular basement membranes is 
required for BMP-7-induced inhibition of cell division in the SVZa, we prevented the binding of 
BMP-7 by deglycanation (performing two successive injections of both heparitinase-1 and BMP-
7) prior to assessing cell proliferation in the SVZa. The loss of BMP-7 binding to fractones and 
SVZa blood vessels almost restored the basic rate of cell proliferation (Figs. 3c and 3d, and 
detailed cell counts in supplemental Table 1). This suggests that the inhibitory effect of BMP-7 
on cell proliferation requires BMP-7 capture by fractones and vascular basement membranes. 
Although the binding of BMP-7 was more frequently visualized in fractones than in vascular 
basement membranes (Fig. 2), it is impossible to speculate on the relative role of fractones 
versus SVZa as crucial promoters of BMP-7 to mediate the inhibition on cell division in the 
SVZa. To determine the effect of heparitinase-1 on the physiological rate of cell proliferation in 
the SVZa, other groups of mice were treated with injection of heparitinase-1 only. Heparitinase-1 
on its own induced a slight but significant increase of the basic rate of cell proliferation (Figs. 3A 
and 3D, and complete cell counts provided in Table 1). Since these experiments have been 
performed in vivo, it is likely that endogenous growth factors are affected by heparitinase-1, and 
therefore that our results reflect the cumulative effect of heparitinase-1 on the injected plus 
endogenous growth factors. An overall interpretation of the results is provided in the discussion 
of this manuscript. 
 
Co-localisation of FGF-2 binding sites with N-sulfated heparan sulfate domains  
    We previously reported that FGF-2, a mitotic factor in the adult neural stem cell niche28, 
exclusively binds to fractones and vascular basement membranes in the walls of the lateral 
ventricle in the adult mouse8. However, the location of FGF-2 binding along the ventricular 
system was not detailed and the possible co-localization of FGF-2 binding with 
immunoreactivity for N-sulfated heparan sulfate domains (antibody 10E4) was not investigated. 
    FGF-2 was biotinylated and ICV injected in groups of adult mice. The FGF-2 binding sites 
were detected in frozen sections of the brain with streptavidin Texas red. Figs. 4a and 4c show 
that FGF-2 has been exclusively captured by the majority of fractones, vascular basement 
membranes in the SVZa and the choroid plexus in the lateral ventricle. Figures 5a-5C 
demonstrate that FGF-2 has been captured by fractones and SVZa blood vessels along other 
ventricles as well. To determine whether the binding sites of FGF-2 coincide with those of N-
sulfated heparan sulfates, brain sections originating from animals that were injected with 
biotinylated FGF-2 were immunolabeled with the antibody 10E4. FGF-2 binding and 10E4 
immunolabeling coincided in the SVZa and choroid plexus (Figs. 4a and 4b) as indicated by the 
yellow color, overlap of 10E4 labeling (green) and FGF-2 binding (red)  (Fig. 4c). In the SVZa, 
most FGF-2/10E4 immunolabeling was found in fractones, although vascular basement 
membranes were also visualized (Fig. 4c, arrowhead).  
    FGF-2 binding sites matched those of immunoreactivity for N-sulfated heparan sulfates, 
suggesting that FGF-2 binding occurs via NS-HS. To determine whether FGF-2 capture by 
fractones and basement membranes is heparan sulfate-dependant, we injected heparitinase-1 in 
the brain just prior to injecting biotinylated FGF-2. In these experimental conditions, biotinyated 
FGF-2 was not detected in the SVZa (Fig. 6a), whereas some faint labeling was still observed in 
the choroid plexus. This result indicates that FGF-2 is captured by fractones and adjoining 
basement membranes via heparan sulfates. The perfect match between NS-HS immunoreactivity 
and FGF-2 binding further suggests that N-sulfation might be of particular importance for the 
binding. However, since heparatinase-1 cuts the whole heparan sulfate domain of HSPG, it is 
impossible to determine whether this is the loss of N-sulfation or the loss of another sulfation 
pattern that precludes the binding of FGF-2.  
 
FGF-2 binding to fractones and vascular basement membranes of the SVZa is independent 
from the site of intracerebral injection 
    To further explore the capacity of fractones and adjacent vascular basement membranes to 
specifically capture FGF-2, we injected biotinylated FGF-2 in the dorsal cortex, instead of ICV. 
In these conditions, FGF-2 was captured by NS-HS immunoreactive fractones in the SVZa of the 
lateral ventricle (Figs. 5d-5f). This further supports the view that the binding of FGF-2 to 
fractones is specific and independent from the site of injection in the brain. To investigate the 
toxicity of deglycanation in vivo, we examined the dynamic of recovery of NS-HS domains after 
in vivo enzymatic degradation by heparitinase-1, using immunolabeling for 10E4. Figure 6d 
shows that immunoreactivity for 10E4 has fully recovered 48 hours after ICV injection of 
heparitinase-1. Therefore, our in vivo experimental protocol of deglycanation appears 
appropriate for examining the effect of the binding loss on cell division in the SVZa. 
 
FGF-2 cannot efficiently stimulate cell proliferation in the SVZa when co-injected with 
heparitinase-1 
    Finally, to determine whether the mitotic effect of FGF-2 requires the binding of FGF-2 to 
fractones and SVZa basement membranes, we examined the effects of FGF-2 on cell division in 
the SVZa after injection of FGF-2 or after successive injections of heparitinase-1 and FGF-2. 
Cell division was analyzed by counting BrdU immunoreactive cells in the walls of the lateral 
ventricle, using serial coronal sections of the brain, which comprise the SVZa. FGF-2 injected 
alone generated a 390% increase in the rate of cell proliferation in the SVZa, compared to the 
basic rate  (Figs. 7a and 7c). However, when FGF-2 binding was prevented by heparitinase-1 
treatment, the rate of cell proliferation in the SVZa increased by only 50% (Fig. 7f). Complete 
BrdU-immunoreactive cell counts throughout the SVZa are reported in supplemental results, 
table 1 (serial sections cut in the coronal plane). We also performed additional experiments, 
using the same injections but on series of animals in which dividing cells were counted in 
sagitally-cut brain sections (supplemental results, table 2). The results were similar to those 
obtained for coronal sections. These results strongly support the view that FGF-2 binding to 
fractones and SVZa basement membranes is required for the mitogenic effect of FGF-2 in the 
SVZa. Fig. 8 illustrates the interpretation of these results as well as those found for BMP-7. 
 
Discussion 
    The data from this study suggest that BMP-7 and FGF-2 must be captured by heparan sulfates 
located in fractones and SVZ basement membranes to modulate cell division in the SVZ 
neurogenic zone. We show in vivo that heparitinase-1 deglycanation eliminates the specific 
binding of both growth factors to fractones and SVZa basement membranes (Figs. 2 and 6). The 
loss of binding is correlated with reduced stimulatory effect of FGF-2 and reduced inhibitory 
effect of BMP-7 on cell proliferation in the SVZa (Figs. 3 and 7). Heparitinase-1 by itself 
slightly increases the rate of cell division in the SVZa (Fig. 7 and supplemental tables). It is 
likely that heparitinase-1 prevents the activity of endogenous heparin-binding growth factors, 
which together with the injected growth factor contribute to the regulation of cell division in the 
SVZa. Therefore, the results may reflect the cumulative effect of the lack of binding of both 
exogenous and endogenous growth factors to heparan sulfates in fractones and SVZa basement 
membranes. Nevertheless, the high degree of stimulation (390% with FGF-2) and inhibition 
(370% with BMP-7) of cell division, together with the absence of detectable binding and the loss 
of effect of these growth factors on cell division after heparitinase-1 treatment strongly suggest 
that the binding of FGF-2 and BMP-7 to fractones and adjacent basement membranes is required 
for regulating cell division in the SVZa. 
    A remarkable finding is that most fractones of the SVZa collect BMP-7 and FGF-2 (Figs. 2 
and 4). This indicates that an individual fractone can collect growth factors with opposite effects. 
This also suggests that fractones may play a major role as regulators of growth factors, balancing 
both an effect and its opposite to ultimately control the rate of cell division in the SVZ. We 
conclude that heparan sulfates contained at fractones and vascular basement membranes likely 
represent the critical effectors that potentiate BMP-7 and FGF-2 and therefore intervene in the 
bi-directional regulation of cell division in the primary germinal zone of the adult brain.   
    In this study, we have shown that FGF-2 and BMP-7 were partly captured by the stroma of the 
choroid plexus (Figs. 2a and 4a). A brain barrier, formed by a complete wall of tight junctions, 
exists between the stroma (made of meninges) and the epithelium of the choroid plexus29. For 
this reason, BMP-7 and FGF-2 bound in the choroid plexus stroma cannot cross the barrier and 
influence the SVZ. However, the epithelium of the choroid plexus produces growth factors, 
including FGF-230,31. It is possible that the choroid plexus stroma influences cell division in the 
SVZa, indirectly via a growth factor cascade relayed by the epithelium. 
    The importance of heparan sulfates as ECM receptors potentiating growth factors at the site of 
capture has been previously emphasized. Heparan sulfates are linear polysaccharides with 
repeated disaccharide units containing N- and O- sulfate esters at various positions. In vivo, 
heparan sulfates occur as HSPG, with the heparan sulfates attached to a core protein such as 
glypicans32 and syndecans, anchored at the cell surface in the interstitial ECM, or perlecan, agrin 
and collagen XVIII in the basement membranes, the specialized mats of ECM present at the 
interface of the connective tissue with the parenchyma of organs. We have previously identified 
the HSPG perlecan in fractones8. 
    Heparin-binding sites are found in a large number of proteins that operate as mediators and 
that intervene in the regulation of diverse functions such as cell division and differentiation, 
morphogenesis, inflammation and wound healing. These proteins include enzymes, protease and 
esterase inhibitors, pathogens (viral proteins), growth factors, cytokines, chemokines and 
morphogens. To bind their receptors at the cell surface, most mediators requires the presence of 
heparin- (or possibly chondroitin- or keratan-) sulfates present in glycosaminoglycans of the 
ECM, which serve as obligatory co-receptors. More than two decades ago, it became apparent 
that without binding to heparan sulfates, granulocyte macrophage colony stimulating factor 
(GM-CSF) cannot influence hematopoeisis19,20. Soon after, it was demonstrated that FGF-2 must 
bind heparan sulfates, and in particular perlecan, to exert its effect21,22,33. The tripartite molecular 
interactions involve the presentation of FGF-2 to FGFR (FGF receptor) by heparan sulfates, the 
activation of protein kinase cascades by FGFR and ultimately modulation of cell division. 
Additionally, the FGF/heparan sulfate complex enters the cell nucleus by endocytosis to directly 
influence genes that are responsible for cell division23. 
    The interaction of heparan sulfates with mediators in the ECM is not restricted to activation of 
the cell-surface receptors. Heparan sulfates also protect mediators from enzymatic degradation 
and serve as storage for mediator delayed activation34. A third role of heparan sulfates is to 
recruit and activate mediators at specific anatomical sites. Whereas several HSPG such as 
glypicans and syndecans are located in the interstitial matrix at the cell surface32, other HSPG, 
such as perlecan22, agrin35 and collagen XVIII36, are located in basement membranes at the 
interface of the connective tissue with parenchymal cells of any tissue or organ. In the brain, 
basement membranes are located at the interface of the meninges (brain connective tissue) with 
the glia limitans, and in the walls of blood vessels, where the adventitia represents the connective 
tissue1,2,26. Which mediators rely upon heparan sulfates to recognize their cognate receptors on 
the cell surface? A high number of mediators, cytokines, chemokines and ECM molecules are 
heparin binding. Interstitial- as well as the basement membrane- HSPG, have been implicated as 
crucial co-receptors for interaction with a large variety of ligands including growth factors (FGF-
1, FGF-2 and FGF-4 21,22,33,37,38, all other members of the FGF and BMP families, other growth 
factors such as VEGF (vascular endothelial growth factor), HB-EGF (heparin-binding epidermal 
growth factor), neuregulin, chemokines (CC chemokines and CXC chemokines), cytokines IL 
(interleukins) and IFN (interferons) (H. Ibelgauft, Cytokines and cells online 
pathfinder encyclopedia, heparin binding domain), amphiregulin39, GM-
CSF19,20, morphogens such as Shh (sonic hedgehog)40, Noggin and Wnt as well as ephrins and 
ECM molecules such as fibronectin. Therefore, all these heparan sulfate binding molecules are 
candidates for binding/activating by basement membranes or other ECM structures such as 
fractones. This is an attractive possibility when knowing that these molecules regulate 
neurogenesis41,42. For example, Shh affects cell proliferation in the postnatal and adult SVZ43.   
    Interestingly, most vascular basement membranes (besides those of the SVZ) were neither 
immunoreactive for 10E4 nor capturing FGF-2 and BMP-7. This suggests that a subset of ECM, 
immunoreactive for NS-HS, comprising fractones, SVZ vascular basement membranes and 
choroid plexus, is responsible for FGF-2 and BMP-7 capture. It has been shown that defective N 
sulfation limits the binding of heparin-binding growth factors and well as their activity44. 
Therefore, the location of NS-HS immunolabeling (Figs. 2, 4 and 5) may reflect potential niches 
for multiple growth factor binding.  
   The question arises as to how heparan sulfates discriminate growth factors throughout the 
SVZ. It is known that epimerases, sulfatases and sulfotransferases operate in the Golgi apparatus 
and in the extracellular space to produce a high diversity of HS chains45,46. We anticipate that the 
structural diversity of heparan sulfates, together with the diversity of the proteoglycan core 
(perlecan, agrin, collagen XVIII) reflects the binding specificity for heparin-binding growth 
factors throughout the SVZ. The pattern of heparan sulfates and of their sulfation may provide 
specific instruction for capturing a given ligand that will mediate the specificity of 
ligand/receptor interactions and ultimately the biological activity promoted by the ligand. This 
hypothesis has been already successfully examined for axon guidance47.  
     Supporting the strong implication of heparan sulfates in other stem cell niches, it has been 
recently demonstrated in vitro that heparan sulfates act as promoters of mesenchymal stem cell 
proliferation and differentiation48. It is now important to determine whether the 
macrophage/microglia associated with fractones and with the SVZa perivasculature1,2 produce 
HSPG and control the dynamic information encoded within fractones to control cell division. 
Macrophage/microglia can produce HSPG42,49 and are involved in the process of adult 
neurogenesis50.  
 Conclusions  
    Fractones and specialized vascular basement membranes were found to be essential for the 
regulation of cell division by BMP-7 and FGF-2 in the adult neural stem cell niche. This is the 
first characterization of fractone function. Moreover, our experiments suggest that heparan 
sulfates, and particularly those that are N-sulfated, may be crucial chemical effectors of fractones 
and SVZ basement membranes, providing specific ability for growth factor capture and 
activation. This makes the SVZ and its ECM components (fractones and basement membranes) 
unique and particularly suitable for recruiting and dispatching growth factors/cytokines 
originating from the ventricular cavities. Therefore, we propose that fractones along the brain 
ventricular system, i.e. lateral, third, and fourth ventricles, aqueducts and spinal canal, act as 
captors of signaling ligands, selecting and potentiating the ligand functions at a precise and 
controlled location to ultimately organize multiple biological processes, including adult 
neurogenesis in the SVZa and other neural regulatory functions in the rest of the ventricular 
system. 
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FIGURES 
Figure 1. Structure, ultrastructure and distribution of fractones in the adult mammalian brain.  
(a) Schematic representation of a fractone. The fractal structure allows an individual fractone 
(green) to contact the processes of numerous neighboring cells (red). (b) Ultrastructure of an 
individual fractone (arrow) visualized by transmission electron microscopy in the subventricular 
zone (SVZ) of the adult rat. Note the multi-branched (fractal) structure. (c) A fractone contacts 
multiple glial and neural stem cell processes (arrows) in the SVZ covering the corpus callosum 
(CC). (d) Fractones appear as punctae (green) in light microscopy after immunolabeling for N-
sulfated heparan sulfates (NS-HS). Cell nuclei are counterstained with DAPI (blue). Some 
vascular basement membranes in the SVZa are labeled for NS-HS (green) and laminin alpha-1 
(red). (e) Schematic representation of the adult neurogenic zone in the SVZ of the lateral 
ventricle (LV). Fractones (green) are associated with proliferating neuroblasts/neural stem cells 
(red) in the SVZa. Note that the fractones directly contact ependymocytes (Ep), the first cell 
layer of the ventricle wall. Cp: choroid plexus; Ca: caudate nucleus. The inset indicates the 
location of images (c) and (d), and diagram (e). (f) Confocal imaging of the most active germinal 
niche of the adult brain. Adult mouse fractones (visualized by laminin-immunolabeling, green 
punctae, arrow) are associated with dividing cells (BrdU labeling, red) in the SVZ covering the 
Ca (the plane of section is tangential to the Ca surface). The inset shows the location of this 
image in a sagittal diagrammatic view of the brain. Scale bars. b and d: 1 µm; E: 25 µm, h: 100 
µm. 
  
Figure 2. Fractones and SVZa basement membranes capture BMP-7. (a) 22 hours after ICV 
injection, biotinylated-BMP-7 was detected by streptavidin-Texas as multiple punctae (arrow) in 
the SVZ of the lateral ventricle (LV) and in the choroid plexus (CP). CPu: caudate putamen, CC: 
corpus callosum; FH: fimbria hippocampus. (b) Identification of the BMP-7 punctate binding 
sites as fractones (arrow) by 10E4 (NS-HS) immunolabeling (green). Note the strict correlation 
between the sites of binding for BMP-7 (a) and the immunoreactivity for 10E4 (b). (c) 
Magnification of the zone indicated by an arrow in image A, showing that not only fractones 
(arrowheads), but also blood vessels have captured BMP-7 (arrowheads showing truncated blood 
vessels). (d) Same section showing that these blood vessels are immunoreactive for NS-HS. (e) 
Location of images (a-d) in a sagittal representation of the brain. (f) After deglycanation by 
heparitinase-1, fractones cannot capture BMP-7 (absence of BMP-7 detection in the red 
channel). Absence of 10E4 immunolabeling (in the green channel) indicates that heparan sulfates 
have been cut. (g) Same field showing that deglycanation was not detrimental to the visualization 
of fractones by laminin immunoreactivity (Alexa-Fluor 647, displayed in clear-blue). (h) 22 
hours after injection, biotinylated BMP-7 has also been captured by fractones of the fourth 
ventricle (arrow) and by meninges extending up to the fourth ventricle (arrowhead). Green: 10E4 
immunolabel. (i). Same image displaying BMP-7 binding (red) and cell nucleus counterstaining 
(blue). Scale bars. a and c: 1 µm; b, f and g: 25 µm; d, e, i: 100 µm. 
 
Figure 3. BMP-7 must bind fractones and adjacent basement membranes to inhibit cell division 
in the SVZa neurogenic niche. (a) Cell division in the SVZa (coronal section) after two 
successive injections of artificial cerebrospinal fluid (CSF). Dividing cells were visualized by 
bromodeoxyuridine (BrdU) immunolabeling (green). Fractones and SVZa basement membranes 
were visualized by 10E4 immunolabeling (red). Magnified zones (insets) show that cells divide 
near fractones or vascular basement membranes (arrow). The location of images is indicated in 
(d) (between red arrows). (b) Cell division in the SVZa after two successive injections of BMP-
7. BMP-7 has drastically decreased the number of dividing cells. The inset shows rare 
BrdU+cells (green). (c) Cell division in the SVZa after two successive injections of heparitinase-
1+ BMP-7. Heparitinase-1 prevented the inhibition of BMP-7 and restored cell proliferation in 
the SVZa (arrow in inset). (d) Top. Location of images. Bottom. Diagram reporting BrdU+ 
average cell counts per 25 µm-thick section in the different experimental conditions. Scale bars: 
100 µm.  
 
Figure 4. Fractones and SVZ basement membranes capture FGF-2. (a) Binding of biotinylated 
FGF-2 (red) revealed by streptavidin Texas red in a sagittal section 22 hours after ICV injection. 
FGF-2 was concentrated in the SVZ (arrow) and choroid plexus (arrowhead). (b) Same section 
showing immunolabeling for fractones and choroid plexus (10E4, green). The coincidence 
between FGF-2 binding and 10E4 immunolabeling indicates that FGF-2 has been concentrated in 
fractones (arrow) and the choroid plexus (arrowhead). The inset shows the location of the image. 
Ca: caudate nucleus; CC: corpus callosum; LV: lateral ventricle. (c) 2.8x magnification of the 
area indicated by an arrow in (a), showing both FGF-2 binding and 10E4 immunolabeling. 
Nearly all fractones have bound FGF-2 (appear yellow by double labeling) (arrow). Note that 
vascular basement membranes immunoreactive for 104 have bound FGF-2 (arrowhead). Scale 
bars. a: 100 µm; c: 50 µm. 
 
Figure 5. FGF-2 capture by fractones and basement membranes is independent of the injection 
site. (a-c) Binding of FGF-2 visualized by streptavidin Texas red in the SVZ of the third 
ventricle, 22 hours after ICV injection. FGF-2 binding  (red) and immunolabeling for laminin 
(blue), 10E4 (green) and are all displayed in the image a. Image (b) shows 10E4 only and image 
(c) shows FGF-2 binding only. Due to the construction of the third ventricle, fractones appear as 
two parallel lines (arrows). Numerous fractones (arrow in b) have captured and concentrated 
biotinylated FGF-2 (arrow in c). Specific blood vessels of the SVZ have captured FGF-2 (double 
arrow). Most blood vessels did not (arrowheads). The inset indicates the location of images. (d-f) 
22 hours after injection of biotinylated FGF-2 in the dorsal cortex, 10E4 immunolabeling (green, 
in d) and binding of biotinylated FGF-2 (red, in f) are found in fractones of the lateral ventricle 
SVZ. FGF-2 binding and 10E4 are displayed together in (e). Fractones of the lateral ventricle 
SVZ wall have concentrated FGF-2 (arrows in e and f). Note that the choroid plexus also 
concentrated FGF-2. The inset in d indicates the location of images. Scale bars: 100 µm.  
 
Figure 6. The binding of FGF-2 to fractone-heparan sulfates and vascular basement membranes 
is heparin-binding dependant. (a) Absence of biotinylated-FGF-2 binding (streptavidin Texas 
red) 22 hours after ICV injection of biotinylated-FGF-2 and heparitinase-1. No labeling is visible 
in the SVZ (arrow). Note the faint binding in the choroid plexus stroma (arrowhead) (b) Same 
section showing immunolabeling for N-sulfated HS (antibody 10E4). No 10E4 labeling is visible 
in the SVZ or other zones of the brain parenchyma, indicating that heparitinase-1 deglycanation 
was effective. Note that deglycanation was not effective beyond the brain barrier in the choroid 
plexus stroma (arrowhead). (c) Schematic representation of the brain (sagittal plane, 1.3 mm to 
the midline). The arrow indicates the location of the images a, b. (d) Recovery of HSPG chains 
(10E4 immunoreactivity, green) 48 hours after ICV injection of heparitinase-1. The red punctae 
indicate the nuclei of proliferating cells (immunolabeling for BrdU) next to fractones (green 
punctae, arrow) in the SVZ neurogenic zone. Scale bars: 100 µm. 
 
Figure 7. The binding of FGF-2 to fractones is required for the stimulation of cell division in the 
SVZ. (a, c, d, f) Coronal sections showing the index of cell proliferation (BrdU+, red) in the 
anterior SVZ after ICV injections of FGF-2 (a), CSF (c), heparitinase-1 plus FGF-2 (f) or 
heparitinase-1 only (d). Cell division was strongly stimulated by FGF-2 (arrow and arrowhead in 
a; compare a and c). The location of the lateral ventricle, narrow in this location (Bregma + 
1mm) is indicated by a double arrow. (b) Inset showing a x2.5 magnification of the zone 
indicated by an arrow in (a). The right inset indicates the location of images a-f (red arrow). Both 
left and right ventricles are displayed in (a). Cell division was not substantially induced by FGF-
2 when the binding of FGF was inhibited by heparitinase-1 (compare a and f), suggesting that 
FGF-2 binding to fractones was required to stimulate cell proliferation in the SVZ. (e) Diagram 
reporting the average number of proliferating (BrdU+) cells per section per lateral ventricle wall 
(left or right) upon the different experimental conditions. The numbers represent the averages of 
all sections counted (not the number of cells included in the displayed images). Scale bars: 100 
µm. 
 
Figure 8. Interpretation of the results: Fractones and its heparan sulfates as captors, selectors and 
dispatchers of growth factors in the neurogenic zone. (a) FGF-2 and BMP-7, which circulate in 
the cerebrospinal fluid of ventricles, enter through interstitial clefts in between ependymocytes. 
(b) FGF-2 and BMP-7 are captured by the heparan sulfates of fractones. (c) Fractone-heparan 
sulfates target FGF-2 and BMP-7 towards selected cells in the SVZ and facilitate growth factor 
binding to their cognate receptors at the surface of target cells. (d) FGF-2 and BMP-2 have 
docked to their respective cell-surface receptors on selected cells. (e) Promoted by heparan 
sulfates, FGF-2 engages mitosis of the targeted cell, whereas BMP-7 blocks the division of the 
other cell. (f) Mitosis of the cell targeted by FGFG-2 occurred.  
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Materials and Methods 
Animals 
8-10 week old male and female Balb/c mice (n=60) were injected intraperitoneally with 
bromodeoxyuridine (BrdU) (50mg/kg of body weight) (Sigma; St. Louis, MO) and 
stereotaxically into the lateral ventricle (ICV injection, 0.6 mm lateral to the midline, 2 mm 
depth from the dorsal pia) or in the dorsal cortex (2 mm lateral to the midline, 1.5 mm depth 
from the dorsal pia) with heparitinase-1 (32mU/injection, from Flavobacterium heparinum, 
Seikagaku, Japan), FGF-2 (0.5 μg/animal) (Chemicon/InVitrogen, Carlsbad, CA), BMP-7 (0.5 
µg per animal) (10-783-79729, GenWay Biotech, Inc, San Diego, CA). The animal experimental 
protocol followed NIH guidelines and was approved by the Institutional Animal Care and Use 
Committee at the University of Hawaii. 
 
In vivo binding of FGF-2 and BMP-7 
FGF-2 and BMP-7 were biotinylated as described in the EZ-link Micro-sulfo- NHS Biotinylation 
kit, 21425, Pierce, Rockford, IL). 0.5 μg of each biotinylated growth factor was diluted in 
artificial cerebrospinal fluid (Harvard Apparatus, Holliston, MA) and injected by stereotaxy 
(intracerebroventricularly or in the dorsal cortex), following or not heparatinase-1 injection. The 
binding sites of growth factors were revealed on brain frozen sections with streptavidin-Texas 
red. When ICV injections of biotin only or artificial CSF only were carried out, no streptavidin 
Texas red signal was detected in the brain. Native recombinant and biotinylated-FGF-2 and -
BMP-7 were equally active on cell proliferation in the SVZ of the lateral ventricle. As a negative 
control, we injected non-conjugated biotin into animals. Controls did not show any detectable 
label after streptavidin Texas red labeling on frozen sections (data not shown).  
 Microscopy 
The results were recorded with a Zeiss Pascal confocal laser scanning microscope or a digital 
DFC350FX Leica camera mounted on a Leica DMIL epifluorescence microscope. In both cases, 
Plan Apo dry objectives were used. Images were processed with Adobe Photoshop CS3 (Adobe 
Systems, Mountain view, CA). Numerous images displayed (such as Figs. 4A and B, 6E) 
originate from X-Y montages of single images captured with a high magnification objective. 
This allowed us to obtain large fields of view, with a high resolution. Adjustments for brightness 
and contrast were not done or were minimal. Transmission electron microscopy was performed 
as previously published1,25. 
 
Effect of injecting FGF-2, BMP-7, combined or not with heparitinase-1 on cell proliferation 
in the SVZ  
The ICV injections of FGF-2, BMP-7 and/or heparitinase-1 diluted in artificial CSF were 
performed as two subsequent 15 minute-injections in series of four adult mice at day 1, repeated 
at day 3, and the mice were terminated at day 5. The different experimental conditions were as 
follows: CSF + CSF (two subsequent injections of CSF termed CSF condition), CSF + of 0.5 μg 
of growth factor (FGF-2 or BMP-7 condition), heparatinase-1 + growth factor (Hep + FGF-2 or 
BMP-7 condition), or heparitinase-1 + CSF (Hep alone condition). BrdU was injected once six 
hours prior to the animal termination, to detect the majority of cells in S phase mitosis, and BrdU 
immunolabeling performed in series of sagittal or coronal whole brain sections. BrdU+ cells 
were directly counted under the fluorescence microscope using a x20 PlanApo objective in serial 
coronal sections including the SVZ of the lateral ventricle or in serial sagittal sections including 
the SVZ. 
 
Immunocytochemistry 
The immunocytochemistry procedures were performed as described25 on serial frozen sections 
fixed with acetone at -20C. Subsequent immunolabeling with an additional 4% PFA fixation 
prior to 2NHCL treatment was used for BrdU immunocytochemistry. Fractones, blood vessels 
and choroid plexus were labeled with the anti-laminin antibody (L9393, Sigma, St. Louis, MO) 
or the anti-N-sulfate glycosamine antibody (10E4, Seikagaku, Japan), then visualized with 
donkey anti-rabbit conjugated to fluorescein isothiocyanate (FITC) (N1034VS, Amersham, 
Piscataway, NJ) and goat anti-mouse IgM conjugated to Alexa Fluor 488 (A21042, InVitrogen, 
Carlsbad, CA) or donkey anti-mouse IgM conjugated to Cy-3 (Jackson Laboratories, Bar Harbor, 
ME), respectively. Pre-mitotic cells (S-phase) were labeled with anti-BrdU antibodies 
(OBT0030, Oxford Biotechnology, UK) as described in 9, and visualized with goat anti-rat 
Alexa- Fluor 546 or goat anti-rat conjugated to AlexaFluor488 (Molecular Probes/InVitrogen, 
Carlsbad, CA).  
 
Cell counts and statistical Methods 
BrdU+ cells were counted throughout series of whole-brain 25-μm thick coronal and 14 μm-
thick sagittal sections. The serial brain frozen sections were generated with a Leica CM1900 
cryostat and were all identified according to their bregma or lateral coordinates. Cell counts and 
means were calculated and reported per segment of 0.1 mm (supplementary tables 1 and 2). For 
coronal sections, BrdU+ cells counts are reported per lateral ventricle wall. No differences were 
observed between the ventricles located ipsi- and contralateral to the injection site. For sagittal 
sections, cells counts were performed on the SVZ only. Cell division in the rostral migratory 
stream was excluded by anatomical landmarks and by the absence of fractones, indicated by the 
lack of laminin-immunoreactive punctae. The cell proliferation numbers (BrdU+cell numbers) 
were averaged separately for each condition with the respective standard deviation of the means, 
and analyzed by a one-way ANOVA (α= 0.05) followed by a Turkey’s test and a two-sided 
Dunnett’s test to compare each condition to the control (CSF conditions). Multiple comparison 
tests were made by the REQWQ’s procedure. XLStat was used for all analyses. Differences 
between two groups were considered significant when p<0.001. 
 








